Figure 1. Kaplan-Meier Survival Analysis comparing the risk of hospitalization between the groups with 2019 Lupus classification criteria score (CCS) of less than 19 (red) and more/equal to 19 (blue). A time-dependent effect, with the admission free survival curves crossing at two years (Figure 1), indicated a 1 out of 3 chance of lupus related admission during the first 6 months for a high CCS score ≥ 19 .

Conclusion: We failed to validate the EHR algorithm identifying patients at high risk for lupus hospitalization in our less severely affected cohort with fewer admission events to analyze. Nonetheless, "criteria counting" using the weightings of the 2019 lupus classification criteria was granular enough to make these case finding criteria themselves prognostic for future hospitalization risk. It is likely that existing EHRs, using protocols based upon classification criteria scores, are now capable of predicting survival, costs, and admissions automatically.

References:

- [1] D Li et al. Determining risk factors that increase hospitalizations in patients with systemic lupus erythematosus, *Lupus* (2018) 27, 1321–1328
- [2] Carneiro et al. A comparison of three classification criteria sets for Systemic Lupus Erythematosus – a study looking at links to outcome and mortality; *Arthritis Care Res (Hoboken)*. 2019 Sep 10. doi: 10.1002/acr.24061

Disclosure of Interests: Saurav Suman: None declared, Mervat Eissa: None declared, Heidi Rogers: None declared, Aleksander Lenert: None declared, Arnold Stromberg: None declared, William Roberts Shareholder of: Own Stocks of Pfizer and Novartis

DOI: 10.1136/annrheumdis-2020-eular.1752

AB1232

ORAL DYSBIOSIS REFLECTS THE IMMUNOLOGICAL ALTERATION OF RA REGARDING TO ACPA AND HLA-DRB1*SE: NAGASAKI ISLAND STUDY

Y. Tsuji¹, M. Tamai¹, S. Morimoto¹, D. Sasaki¹, M. Nagayoshi², F. Nonaka¹, S. Y. Kawashiri¹, K. Yanagihara¹, T. Saito¹, K. Aoyagi¹, T. Maeda³, F. Matsuda⁴, A. Kawakami¹. ¹Nagasaki University, Nagasaki, Japan; ²National Institute of Public Health, Wako, Japan; ³Nagasaki University, Department of General Medicine, Nagasaki, Japan; ⁴Kyoto University, Kyoto, Japan

Background: Anti-citrullinated protein antibody (ACPA) production is observed in several organs even prior to the onset of rheumatoid arthritis (RA), and oral mucosa is considered to be one of the important tissues. The presence of HLA-DRB1*SE closely associates with ACPA production. Saliva is considered to reflect the oral microbiota including periodontal disease. Alteration of oral microbiota of RA becomes to be normalized by DMARDs treatment, however, the interaction of HLA-DRB1*SE, ACPA and oral microbiota of RA patients remains to be elucidated.

Objectives: The Nagasaki Island Study, which had started in 2014 collaborating with Goto City, is intended for research of the preclinical stage of RA, including ACPA/HLA genotype screening and ultrasound and magnetic resonance imaging examinations in high-risk subjects. Using the samples accumulated in this cohort, we have tried to investigate the difference of oral microbiota among RA patients and healthy subjects regarding to ACPA and HLA-DRB1*SE.

Methods: Blood and salivary samples were obtained from 1422 subjects out of 4276 who have participated in the Nagasaki Island Study from 2016 to 2018. ACPA positivity was 1.7 % in total. Some of RA patients resided in Goto City participated in the Nagasaki Island Study. At this point, we selected 291 subjects, who were ACPA positive non-RA healthy subjects (n=22) and patients with RA (n=33, 11 subjects were ACPA positive and 22 ACPA negative respectively) as the case, age and gender matched ACPA negative non-RA healthy subjects (n=236) as the control. ACPA was measured by an enzyme-linked immunosorbent assay, and HLA genotyping was quantified by next-generation sequencing (Ref.1). The

operational taxonomic unit (OUT) analysis using 16S rRNA gene sequencing were performed. The richness of microbial diversity within-subject (alpha diversity) was scaled via Shannon entropy. The dissimilarity between microbial community composition was calculated using Bray-Curtis distance as a scale, and differences between groups (beta diversity) were tested by permutational multivariate analysis of variance (PERMANOVA). In addition, UniFrac distance calculated in consideration of the distance on the phylogenetic tree were performed.

Results: Median age 70 y.o., % Female 58.8 %. Among RA and non-RA subjects, not alpha diversity but beta diversity was statistically significance (p=0.022, small in RA). In RA subjects, both alpha and beta diversity is small (p<0.0001), especially significant in ACPA positive RA (Figure 1). Amongst RA subjects, presence of HLA-DRB1*SE did not show the difference but the tendency of being small of alpha diversity (p=0.29).

Conclusion: Our study has suggested for the first time the association of oral microbiota alteration with the presence of ACPA and HLA-DRB1*SE. Oral dysbiosis may reflect the immunological status of patients with RA.

References:

- [1] Kawaguchi S, et al. *Methods Mol Biol* 2018;1802: 22

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2020-eular.5147

AB1233

GENDER DIFFERENCE IN DISEASE SEVERITY AND TREATMENT OUTCOMES AMONG PATIENTS WITH RHEUMATOID ARTHRITIS (RA), AXIAL SPONDYLOARTHRITIS (AXSPA) AND PSORIATIC ARTHRITIS (PSA) STARTING TREATMENT WITH TARGETED THERAPY IN THE CZECH REPUBLIC

J. Zavada¹, L. Nekvindova², K. Pavelka¹, P. Horak³, J. Vencovsky¹ on behalf of collaborators of the ATTRA registry. ¹Institute of Rheumatology, Prague, Czech Republic; ²Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic; ³Faculty of Medicine and Dentistry, Palacký University, 3rd Department of Internal Medicine-Nephrology, Rheumatology, Endocrinology, Olomouc, Czech Republic

Background: The ATTRA registry captures more than 95% of patients with RA, AxSpA, or PSA treated with biologics in the Czech Republic (CZ). In CZ, anti-TNF therapy is reimbursed for RA if DAS28>5.1 despite therapy with csDMARDs, for PSA if disease is not "adequately controlled" with csDMARDs and for AS if BASDAI>4 and CRP/ESR elevated above normal.

Objectives: We aimed to investigate gender-related differences in baseline characteristics and treatment effectiveness among patients with RA, AxSpA, and PSA starting first targeted therapy (TT) in CZ.

Methods: In this observational cohort study, the ATTRA register prospectively collected data on RA, AxSpA and PsA patients who initiated their first TT (mostly by TNFi) in 2012–6/2018. Treatment effectiveness and adherence was assessed at 12 months by a change in patient-reported outcomes (PROs), CRP and % drug survival. Differences in categorical and continuous data btw males and females were assessed using the Pearson χ^2 test (of Fisher exact test, as appropriate), or Mann-Whitney test resp. This study was largely descriptive, and no statistical adjustments have been made.

Results: A total of 1602 RA, 1306 AxSpA, and 493 PsA patients were included. The difference in baseline characteristics btw women and men starting TT are shown in table 1. Their response and adherence to TT after one year is shown in table 2.

Conclusion: When starting their first TT, males tended to have higher levels of CRP, while females were more often (ex)smokers and reported worse parameters of quality of life across the diagnostic groups. The improvement of PROs was similar in males and females, while males with axSpA and PsA showed larger improvements in CRP. Survival on drug at one year was similar, save for AxSpA, where males showed better survival.

References:

	RA (n=1602)			AxSpA (n=1306)			PSA (n=493)		
	M	F	p	M	F	p	M	F	p
N (%)	359 (22.4%)	1243 (77.6%)		931 (71.3%)	375 (28.7%)		262 (53.1%)	231 (46.9%)	
Age (yrs) at start of first symptoms	47.4 (37.1; 54.5)	42.8 (33.3; 51.4)	<0.001	25.5 (19.6; 33.0)	28.6 (21.6; 36.6)	<0.001	36.7 (27.7; 46.5)	38.8 (30.8; 47.5)	0.083
Age (yrs) at diagnosis	48.0 (37.0; 55.0)	44.0 (34.0; 53.0)	<0.001	31.0 (24.0; 39.0)	35.0 (27.0; 42.0)	<0.001	37.0 (30.0; 47.0)	38.0 (32.0; 48.0)	0.171
Age (yrs) at start of first TT	55.0 (46.0; 63.0)	53.0 (43.0; 62.0)	0.076	38.0 (32.0; 47.0)	42.0 (34.0; 50.0)	<0.001	48.0 (37.0; 55.0)	49.0 (40.0; 58.0)	0.070
Smoker or ex-smoker	189 (58.3%)	729 (65.9%)	<0.001	447 (55.6%)	197 (57.4%)	<0.001	100 (43.3%)	132 (63.2%)	0.168
CRP (mg/l)	16.5 (9.0; 32.0)	14.0 (6.0; 28.0)	<0.001	20.0 (11.9; 32.0)	16.0 (10.4; 26.0)	<0.001	16.3 (8.0; 31.8)	15.0 (6.1; 28.7)	0.023
VAS pain (0–100)	70.0 (50.0; 80.0)	70.0 (55.0; 80.0)	0.007	70.0 (50.0; 80.0)	70.0 (55.0; 80.0)	0.292	65.0 (45.0; 80.0)	70.0 (60.0; 80.0)	0.001
VAS fatigue (0–100)	65.0 (50.0; 80.0)	70.0 (55.0; 85.0)	<0.001	65.0 (50.0; 80.0)	70.0 (55.0; 85.0)	<0.001	60.0 (45.0; 80.0)	75.0 (55.0; 85.0)	<0.001
HAQ	1.4 (1.0; 1.8)	1.6 (1.3; 2.0)	<0.001	1.1 (0.8; 1.5)	1.3 (0.8; 1.8)	<0.001	1.3 (0.9; 1.5)	1.5 (1.0; 1.9)	<0.001
EQ-5D (0–1)	0.2 (0.1; 0.7)	0.1 (0.0; 0.6)	<0.001	0.2 (0.1; 0.7)	0.2 (0.1; 0.6)	0.035	0.2 (0.1; 0.7)	0.1 (0.1; 0.6)	0.005

Values are median (IQR) if not stated otherwise.